Lilly Humalog European Labeling Adds HbA1c Lowering Claim

 
• By The Pink Sheet

Revised EU labeling for Lilly's Humalog (insulin lispro) includes a claim that the insulin analog reduces hemoglobin A1c more effectively than soluble insulin when administered in subcutaneous infusion pumps.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet